Be careful if holding a short position,if news hits like rumored, short profits could avaporare in a blink of an eye.
Recent NRXP News
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/18/2026 11:00:00 AM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 05/14/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality • GlobeNewswire Inc. • 05/07/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality • GlobeNewswire Inc. • 04/20/2026 11:00:00 AM
- NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer • GlobeNewswire Inc. • 04/13/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application • GlobeNewswire Inc. • 04/06/2026 11:00:00 AM
- Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 • GlobeNewswire Inc. • 03/19/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application • GlobeNewswire Inc. • 03/17/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD • GlobeNewswire Inc. • 03/09/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date • GlobeNewswire Inc. • 01/16/2026 12:03:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval • GlobeNewswire Inc. • 01/14/2026 12:03:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions • GlobeNewswire Inc. • 01/05/2026 11:57:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion • GlobeNewswire Inc. • 12/18/2025 12:05:00 PM
- NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation • GlobeNewswire Inc. • 12/03/2025 12:00:00 PM
- NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine • GlobeNewswire Inc. • 12/02/2025 01:30:00 PM
- NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call • GlobeNewswire Inc. • 12/02/2025 12:30:00 PM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025 • GlobeNewswire Inc. • 11/12/2025 01:31:00 PM
